Report cover image

Autoimmune Disease Drugs Market by Indication (Diabetes Mellitus Type 1, Multiple Sclerosis, Rare Diseases), Drug Class (Anti-Inflammatory, Antihyperglycemic, Immunosuppressants), Distribution - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 191 Pages
SKU # IRE18418641

Description

Autoimmune Disease Drugs Market by Indication (Diabetes Mellitus Type 1, Multiple Sclerosis, Rare Diseases), Drug Class (Anti-Inflammatory, Antihyperglycemic, Immunosuppressants), Distribution - Global Forecast 2024-2030


The Autoimmune Disease Drugs Market size was estimated at USD 108.71 billion in 2023 and expected to reach USD 116.79 billion in 2024, at a CAGR 7.52% to reach USD 180.67 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Autoimmune Disease Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Autoimmune Disease Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Autoimmune Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AESKU.GROUP GmbH & Co. KG, AstraZeneca PLC, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, Biogenuix Medsystems Private Limited, bioMerieux S.A., Exagen, Inc., F. Hoffmann-La Roche AG, Novartis AG, Pfizer, Inc., Sanofi S.A., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, and Werfen S.A..

Market Segmentation & Coverage

This research report categorizes the Autoimmune Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Indication

Diabetes Mellitus Type 1
  • Multiple Sclerosis
  • Rare Diseases
  • Rheumatic Diseases
  • Drug Class

    Anti-Inflammatory
  • Antihyperglycemic
  • Immunosuppressants
  • Interferons
  • Nonsteroidal Anti-Inflammatory Drugs
  • Distribution

    Hospital Pharmacies
  • Online Stores
  • Retail Pharmacies
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Autoimmune Disease Drugs Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Autoimmune Disease Drugs Market?
    3. What are the technology trends and regulatory frameworks in the Autoimmune Disease Drugs Market?
    4. What is the market share of the leading vendors in the Autoimmune Disease Drugs Market?
    5. Which modes and strategic moves are suitable for entering the Autoimmune Disease Drugs Market?


    Note: PDF & Excel + Online Access - 1 Year

    • Table of Contents

    191 Pages
    1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Autoimmune Disease Drugs Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Increasing incidence of autoimmune diseases rheumatoid arthritis, graves and hashimoto's thyroid disease
    5.1.1.2. Growing awareness of autoimmune diseases
    5.1.1.3. Improved government assistance, funding, and reimbursement policies
    5.1.2. Restraints
    5.1.2.1. Associated side effects of autoimmune disease drugs
    5.1.3. Opportunities
    5.1.3.1. Advancements and availability of late-stage pipeline drugs
    5.1.3.2. Ongoing research and innovations in autoimmune disease drugs
    5.1.4. Challenges
    5.1.4.1. High cost of autoimmune disease medications
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Autoimmune Disease Drugs Market, by Indication
    6.1. Introduction
    6.2. Diabetes Mellitus Type 1
    6.3. Multiple Sclerosis
    6.4. Rare Diseases
    6.5. Rheumatic Diseases
    7. Autoimmune Disease Drugs Market, by Drug Class
    7.1. Introduction
    7.2. Anti-Inflammatory
    7.3. Antihyperglycemic
    7.4. Immunosuppressants
    7.5. Interferons
    7.6. Nonsteroidal Anti-Inflammatory Drugs
    8. Autoimmune Disease Drugs Market, by Distribution
    8.1. Introduction
    8.2. Hospital Pharmacies
    8.3. Online Stores
    8.4. Retail Pharmacies
    9. Americas Autoimmune Disease Drugs Market
    9.1. Introduction
    9.2. Argentina
    9.3. Brazil
    9.4. Canada
    9.5. Mexico
    9.6. United States
    10. Asia-Pacific Autoimmune Disease Drugs Market
    10.1. Introduction
    10.2. Australia
    10.3. China
    10.4. India
    10.5. Indonesia
    10.6. Japan
    10.7. Malaysia
    10.8. Philippines
    10.9. Singapore
    10.10. South Korea
    10.11. Taiwan
    10.12. Thailand
    10.13. Vietnam
    11. Europe, Middle East & Africa Autoimmune Disease Drugs Market
    11.1. Introduction
    11.2. Denmark
    11.3. Egypt
    11.4. Finland
    11.5. France
    11.6. Germany
    11.7. Israel
    11.8. Italy
    11.9. Netherlands
    11.10. Nigeria
    11.11. Norway
    11.12. Poland
    11.13. Qatar
    11.14. Russia
    11.15. Saudi Arabia
    11.16. South Africa
    11.17. Spain
    11.18. Sweden
    11.19. Switzerland
    11.20. Turkey
    11.21. United Arab Emirates
    11.22. United Kingdom
    12. Competitive Landscape
    12.1. FPNV Positioning Matrix
    12.2. Market Share Analysis, By Key Player
    12.3. Competitive Scenario Analysis, By Key Player
    13. Competitive Portfolio
    13.1. Key Company Profiles
    13.1.1. Abbott Laboratories
    13.1.2. AESKU.GROUP GmbH & Co. KG
    13.1.3. AstraZeneca PLC
    13.1.4. Beckman Coulter, Inc.
    13.1.5. Bio-Rad Laboratories, Inc.
    13.1.6. BioAgilytix Labs, LLC
    13.1.7. Biogenuix Medsystems Private Limited
    13.1.8. bioMerieux S.A.
    13.1.9. Exagen, Inc.
    13.1.10. F. Hoffmann-La Roche AG
    13.1.11. Novartis AG
    13.1.12. Pfizer, Inc.
    13.1.13. Sanofi S.A.
    13.1.14. Siemens Healthineers AG
    13.1.15. Thermo Fisher Scientific Inc.
    13.1.16. Trinity Biotech PLC
    13.1.17. Werfen S.A.
    13.2. Key Product Portfolio
    14. Appendix
    14.1. Discussion Guide
    14.2. License & Pricing
    FIGURE 1. AUTOIMMUNE DISEASE DRUGS MARKET RESEARCH PROCESS
    FIGURE 2. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2023 VS 2030
    FIGURE 3. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. AUTOIMMUNE DISEASE DRUGS MARKET DYNAMICS
    FIGURE 7. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
    FIGURE 8. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
    FIGURE 10. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
    FIGURE 12. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 14. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 16. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 22. AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us